Steatosis News and Research

RSS

Newcastle scientists develop new type of genetic blood test to diagnose liver scarring

Newcastle scientists and medics have developed a new type of genetic blood test that diagnoses scarring in the liver - even before someone may feel ill.

11 Apr 2016

Researchers find prevalence of steatosis in liver transplant recipients

Researchers have characterized the prevalence and risk factors of fatty liver disease in patients who undergo liver transplantation. The findings, which are published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases, could have important implications for safeguarding transplant recipients' health.

6 Apr 2016

Absence of PEMT enzyme leads to development of fatty liver disease and tumours in thin patients

Researchers observe protection against obesity and insulin resistance but at the cost of prominent fatty liver disease in mice lacking the PEMT enzyme and patients with low levels of PEMT.

7 Mar 2016

Potential treatment target identified for fatty liver disease

Two proteins, p38 gamma and p38 delta, control the accumulation of fat in the liver, a process linked to the development of insulin resistance and diabetes, which are common outcomes of obesity. These findings are presented in an article published by researchers at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC).

4 Feb 2016

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to conduct a Phase 2 study of VK2809 in patients with hypercholesterolemia and fatty liver disease.

17 Nov 2015

Georgia State University researcher receives $1.35 million federal grant to study effects of emulsifiers

Andrew Gewirtz, a professor in the Institute for Biomedical Sciences at Georgia State University, has received a four-year, $1.35 million federal grant to study how emulsifiers affect bacteria in the intestinal tract and cause chronic inflammatory diseases in the gut.

6 Oct 2015

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

Isis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, and Akcea Therapeutics, its wholly owned subsidiary, announced today that The New England Journal of Medicine (NEJM) has published positive clinical results from a Phase 2 clinical study evaluating volanesorsen (formerly ISIS-APOCIII Rx) in patients with very high to severely high triglycerides.

30 Jul 2015

NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

Nutrition Science Initiative has launched the first-ever randomized, controlled clinical trial to determine whether removing added sugars from the diet can halt or even reverse nonalcoholic fatty liver disease (NAFLD) in children.

16 Jul 2015

Study shows NASH linked to 50% higher death rates compared with NAFLD

Results from a large population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those with non-alcoholic fatty liver disease (NAFLD).

25 Apr 2015

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Data presented today at The International Liver Congress 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

23 Apr 2015

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 (“miR-103/107”) for the treatment of Non Alcoholic Steatohepatitis (“NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies’ strategic alliance to discover, develop and commercialize microRNA therapeutics.

9 Apr 2015

Scientists develop computer model to predict how liver stores fat

As part of an effort to understand how an experimental drug for atherosclerosis causes the build-up of fat in the liver, scientists have developed a computer model that can predict how the rate at which liver stores fat in response to various situations. Being able to model liver fat storage gives researchers a way to predict the side effects of drugs and environmental factors at much earlier stages in the research and drug development process, possibly reducing the number of experiments involving animal models.

2 Apr 2015

Exposure to hormone-disrupting chemicals can cause fatty liver disease, promote obesity

Exposure to low doses of hormone-disrupting chemicals early in life can alter gene expression in the liver as well as liver function, increasing the susceptibility to obesity and other metabolic diseases in adulthood, a new study finds.

9 Mar 2015

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients.

4 Dec 2014

Component of Glycyrrhiza uralensis plant may thwart development of metabolic disorders

New research published in the December 2014 issue of the Journal of Leukocyte Biology, shows that a component found in in the plant, Glycyrrhiza uralensis, may inhibit the development of metabolic disorders by stopping the activation of NLRP3, a protein involved in the disease process.

2 Dec 2014

Magnetic resonance: A good method for detecting and quantifying fats in the liver

Obesity and overweight affect more than half of the population in our Community. Excess weight causes important alterations in the organism, one of which affects liver function. Fat accumulates in the liver producing hepatic steatosis which, in certain circumstances, causes inflammation, fibrosis and finally, cirrhosis.

18 Sep 2014

Steatosis News and Research

Newcastle scientists develop new type of genetic blood test to diagnose liver scarring

Researchers find prevalence of steatosis in liver transplant recipients

Absence of PEMT enzyme leads to development of fatty liver disease and tumours in thin patients

Potential treatment target identified for fatty liver disease

Viking submits IND application to FDA to conduct VK2809 Phase 2 study in patients with LDL-C and fatty liver disease

Georgia State University researcher receives $1.35 million federal grant to study effects of emulsifiers

NEJM publishes positive clinical results from Phase 2 clinical study of volanesorsen

NuSI launches groundbreaking clinical study to halt nonalcoholic fatty liver disease in children

Study shows NASH linked to 50% higher death rates compared with NAFLD

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

Scientists develop computer model to predict how liver stores fat

Exposure to hormone-disrupting chemicals can cause fatty liver disease, promote obesity

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Component of Glycyrrhiza uralensis plant may thwart development of metabolic disorders

Magnetic resonance: A good method for detecting and quantifying fats in the liver

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

Consumption of probiotics during 30 days helps diminish accumulation of fat in liver

Snacking linked with abdominal fat and fatty liver

Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News